Preliminary assessment of the relative toxicity of R13-36161 in animals (U) Army Environmental Hygiene Agency Aberdeen Proving Ground MD G J Leach Sep 86
PRELIMINARY ASSESSMENT OF THE RELATIVE TOXICITY OF
AI3-36161 IN ANIMALS
STUDY NO. 75-51-0530-86
MARCH 1985 - JULY 1986

Approved for public release; distribution unlimited.
Preliminary toxicity data are presented for Candidate cockroach repellent A13-36161. These data are intended to provide guidance in selecting compounds for further entomological and toxicological evaluations. The rat oral approximate lethal dose was found to be 987 mg/kg. This compound caused moderate to severe skin and eye irritation in rabbits. It was not mutagenic in the Ames test and was not a sensitizer in guinea pigs. A number of cardiovascular alterations were noted in anesthetized rats injected with sublethal doses of A13-36161. This compound was not an inhalation hazard at room temperatures; however, if heated, its vapors may reach concentrations which could cause skin, eye and respiratory irritation.
SUBJECT: Preliminary Assessment of the Relative Toxicity of A13-36161 in Animals, Study No. 75-51-0530-86, March 1985 - July 1986

Executive Director
Armed Forces Pest Management Board
Forest Glen Section, WRAMC
Washington, DC 20307-5001

EXECUTIVE SUMMARY

The purpose and a summary of the recommendations of the enclosed report follow:

a. Purpose. To provide preliminary toxicity data for the candidate cockroach repellent A13-36161. These data are intended to provide guidance in selecting compounds for further entomological and toxicological evaluation. In addition, the data may be useful in developing preliminary safety guidelines for handling this compound.

b. Recommendations. Based on professional scientific judgment, the following recommendations are offered.

(1) A13-36161 should be considered for more extensive entomological and toxicological testing.

(2) This compound can cause severe skin and eye damage. Personnel handling A13-36161 should avoid contact with the skin and eyes. Protective gloves and a face shield or goggles should be worn when handling.

FOR THE COMMANDER:

N. Joe Thompson
Colonel, MC
Director, Occupational and Environmental Health

CF:
HQDA (DASG-PSP) (wo/encl)
Comdt, AHS (HSHA-IPM) (w/encl)
Dir, Advisory Cen on Tox, NRC (2 cy) (w/encl)
USDA, ARS (Dr. Terrence McGovern) (w/encl)
USDA, ARS - Southern Region (w/encl)
Cdr, USMRDC (SGRD-DPM/COL Reinert) (w/encl)
PRELIMINARY ASSESSMENT OF THE RELATIVE TOXICITY OF AI3-36161 IN ANIMALS
STUDY NO. 75-51-0530-86
MARCH 1985 - JULY 1986

1. AUTHORITY.
   b. Memorandum of Understanding between the US Army Environmental Hygiene Agency; the US Army Health Services Command; the Department of the Army, Office of The Surgeon General; the Armed Forces Pest Control Board and the Department of Agriculture, Agricultural Research, Science and Education Administration; titled, Coordination of Biological and Toxicological Testing of Pesticides, effective 23 January 1979.

2. REFERENCES.
   c. Standing Operating Procedures, HSHB-OT, Toxicology Division, USAEHA.

3. PURPOSE. To provide preliminary toxicity data for the candidate cockroach repellent AI3-36161. This report summarizes the toxicological data for USDA candidate cockroach repellent AI3-36161. These data are intended to be used in selecting compounds for more extensive entomological and toxicological testing. The data may also be used in establishing preliminary safety guidelines for handling the material.

4. BACKGROUND.
   a. General. The preliminary toxicological evaluation of candidate cockroach repellents consists of a series of acute screening tests designed
Study No. 75-51-0530-86, March 1985 – July 1986

to assess potential hazards from single exposures by various routes of administration. The test battery included:

1. Rat oral approximate lethal dose (ALD).
2. Primary irritation (skin and eye).
3. Dermal sensitization.
4. Saturated vapor (inhalation hazard).
5. Physiological screen.

b. Project Information.

1. All raw data from this study may be found in project file number 75-51-0530-86 or USAEHA Laboratory Notebooks Numbered 106, 114 and 115.

2. In conducting the studies described in this report, the investigators adhered to the document referenced in 2a. In addition, these studies were performed in animal facilities fully accredited by the American Association for the Accreditation of Laboratory Animal Care.

5. PROCEDURES.

a. Test Compound. Two lots (b & c) of A13-36161 were synthesized and supplied for use in the toxicological evaluations by Dr. Terrence McGovern, USDA, Beltsville, Maryland. A13-36161 is a clear oily liquid with a sweet odor. It exhibits low solubility in water but is soluble in acetone and other organic solvents. It has a molecular weight of 195 and boils at 74 °C at 0.1 mm Hg.

b. Methods.

1. Acute Toxicity Tests. Detailed descriptions of the methodology for tests (a) through (d) listed below are published in reference 2b. Methodology for the saturated vapor test is published in reference 2c.

(a) Rat ALD.

(b) Skin irritancy.

(c) Eye irritancy.

(d) Dermal sensitization (Buehler technique).

(e) Saturated vapor.
Study No. 75-51-0530-86, March 1985 - July 1986

(2) Mutagenicity. Mutagenicity testing was performed by Hazleton Biotechnologies Company under contract DAAD05-86-M-L723 with USAEHA. A complete description of the methodology and results may be found in the final report (reference 2d).

(3) Physiological Screening. The physiological screening tests were designed to obtain basic information on the underlying mechanisms of action for this compound. Male Sprague Dawley rats weighing between 270 - 380 gms were anesthetized with sodium pentabarbital (30 mg/kg). A heparinized cannula (15 cm length of PE50 tubing) was inserted into the left carotid artery for blood pressure monitoring. A similar catheter was inserted into the right external jugular vein for drug injection. A Statham P23-AC fluid filled pressure transducer (Gould Instruments) was used for blood pressure monitoring. The signals were processed by a Buxco Model 6 Pulmonary Function Analyzer (Buxco Electronics) and printed on a Texas Instruments® Silent 700 terminal. EKG's were monitored from LEAD II and fed through a pre-amplifier and Buxco EKG analyzer. A digital recording of wave heights and intervals was printed on a second Texas Instruments TI terminal. Following a short period of time, usually 10-15 minutes, stable physiological recordings were obtained and the animals were treated with challenge doses of standard pharmacological drugs including epinephrine, nor-epinephrine, acetylcholine and histamine. Saline injections served as a volume control. Preliminary experiments were performed in order to find optimum dosage levels. In most cases, the dosage chosen produced a marked change in blood pressure (10-50 mm Hg) lasting less than 5 minutes. Following the initial drug challenges, the test compound AI3-36161 was injected intraperitoneally, and the drug challenges were repeated 15 minutes post injection. For each drug, the maximum change from baseline condition was recorded and the pre- and post-dosing values compared. In this way, each animal served as its own control. The data were analyzed using a two-way analysis of variance with repeated measures program on an IBM® PC microcomputer. A least significant range test was used to compare pre and post-dosing values. A probability of less than 0.05 was used as the level of significance.

6. RESULTS.

a. ALD. The rat oral ALD was found to be 987 mg/kg (Appendix A, Table A-1). This was the lowest dose that produced lethailities. All animals treated with AI3-36161 (as little as 130 mg/kg) exhibited marked salivation. Animals receiving the ALD or higher dose died between 50 minutes and 18 hours post administration. Post mortem examination of the rats that died indicated hemorrhagic areas in the stomach and a bloody exudate from the mouth and nares.

*Texas Instruments is a registered trademark of Texas Instruments, Incorporated, Houston, Texas.

*IBM is a registered trademark of IBM Corporation, Boca Raton, Florida.
b. Skin Irritation. Compound AI3-36161 produced a total irritancy score of 7.42 in the Draize rabbit skin irritancy test. A description of the scoring system employed in these tests is provided at Appendix B. Based on this scoring system, AI3-36161 would be considered a moderate to severe skin irritant. Scurf and/or eschar formation was evident at 1 week post application.

c. Eye Irritation. Based on our Draize eye test in rabbits, this compound is a moderate eye irritant with a total irritancy score of 32.67. It produced injury to both cornea and conjunctiva and the animals exhibited delayed healing and delayed inflammatory changes. Washing the eyes with water immediately post application did not reduce the severity of the injury.

d. Skin Sensitization. Challenge doses of AI3-36161 did not produce a reaction in pretreated guinea pigs and, based on these data, it is not considered to be a sensitizer.

e. Saturated Vapor. Data from the saturated vapor test are summarized in Tables A-1 and A-2 (Appendix A). The test protocol was modified resulting in 5 animal exposure groups in two separate tests. During the initial test (control, room temperature, high temperature groups) the high temperature bubbler was held at 50 °C rather than 100 °C. In the second test, a group of rats was exposed using a 100 °C bubbler system and there was a concurrent air exposed control group. Nominal exposure concentrations for the room temperature, 50 °C and 100 °C bubblers were 0.04 mg/L, 0.18 mg/L and 10.81 mg/L, respectively. Rats exposed to the highest concentration exhibited excessive salivation and rapid breathing, indicative of a respiratory irritant. Twenty four hours post exposure, all animals appeared normal. There were no deaths in any of the experimental groups during the 8 hour exposure period or during the 14 day post exposure period.

f. Physiological Studies. Table A-3 (Appendix A) illustrates the cardiovascular effects of exposure to sublethal intraperitoneal injections of AI3-36161. The values presented represent the maximum change from resting or baseline levels in response to injections of the challenge drug. Due to the toxicity of AI3-36161 when administered intraperitoneally we found it necessary to reduce the dosage to 0.25 times the oral ALD or 247 mg/kg. At this dose, there were significant decreases in blood pressure responsiveness to nor-epinephrine and histamine. In addition, electrical activity in the heart was altered with a decreased p wave height when pre- and post-exposure saline injection values were compared and in response to epinephrine, nor-epinephrine and histamine. A similar trend was noted in the r wave height as well as heart rate and blood pressure however, these differences were not statistically significant. Taken together, these changes in blood pressure and electrical activity in the heart suggest that AI3-36161 may be acting directly on the myocardium as a cellular toxin. Additional physiological studies are required in order to rule out any central nervous system effects as well as other potential toxic actions.
g. Mutagenicity. AI3-36161 did not exhibit mutagenic activity under the test conditions employed. It was negative in all test strains used (Salmonella typhimurium strains TA-1535, TA-1537, TA-1538, TA-98 and TA-100) and at dosages ranging from .1 µL to 25 µL per plate both activated and nonactivated test systems (reference 2d).

7. CONCLUSIONS. Compound AI3-36161 is moderately toxic by the oral route of exposure. It is a moderate to severe eye and skin irritant. This compound presents no acute inhalation hazard at room temperatures though at higher temperatures or if the repellent is atomized as an aerosol, it may cause skin, eye and respiratory irritation. We found no indication of a sensitization reaction and it was not mutagenic in the Ames test. When administered at approximately 0.25 x the ALD to anesthetized, catherized rats, there were changes in blood pressure and electrical activity in the heart which suggest a toxic effect on the myocardium.

8. RECOMMENDATIONS. The following recommendations are based on professional scientific judgment.

   a. AI3-36161 should be considered for more extensive entomological and toxicological testing. Toxicological tests should include a more detailed evaluation of acute toxicity by multiple routes of administration, an assessment of the effects of repeated dosing and a complete evaluation of mutagenic potential.

   b. This compound can cause severe skin and eye damage. Personnel handling AI3-36161 should avoid contact with skin, eyes or clothing. Protective gloves and a face shield or goggles should be worn while handling.

9. ACKNOWLEDGEMENT. The project personnel shown in Appendix C assisted in the experiments.

   GLENN J. LEACH
   Biologist
   Toxicology Division

APPROVED:

   MAURICE H. WEEKS
   Chief, Toxicology Division
APPENDIX A

RESULTS

TABLE A-1. SUMMARY OF TOXICITY DATA CANDIDATE COCKROACH REPELLENT AI3-36161

<table>
<thead>
<tr>
<th>ALD (Mg/Kg)</th>
<th>Skin Category</th>
<th>Eye Category</th>
<th>Sensitization</th>
<th>Sat Vapor</th>
<th>Physio</th>
<th>Ames</th>
</tr>
</thead>
<tbody>
<tr>
<td>987</td>
<td>IV</td>
<td>E</td>
<td>Negative</td>
<td>No deaths</td>
<td>BP and ECG</td>
<td>Negative</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>High conc-irritant</td>
<td>changes</td>
<td></td>
</tr>
</tbody>
</table>

A-1
### TABLE A-2. SUMMARY OF SATURATED VAPOR RESULTS COMPOUND AI3-36161

<table>
<thead>
<tr>
<th>Parameter/Test Group</th>
<th>BW (grams)</th>
<th>LW x100</th>
<th>KW x100</th>
<th>HW x100</th>
<th>LGW x100</th>
<th>TH x100</th>
<th>BRW x100</th>
<th>SW x100</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control-1</td>
<td>230 ± 6</td>
<td>5.845 ± 0.127</td>
<td>1.060 ± 0.030</td>
<td>0.484 ± 0.023</td>
<td>0.708 ± 0.046</td>
<td>0.984 ± 0.024</td>
<td>0.788 ± 0.016</td>
<td>0.364 ± 0.036</td>
</tr>
<tr>
<td>Room-Temp</td>
<td>237 ± 3</td>
<td>5.792 ± 0.165</td>
<td>0.999 ± 0.047</td>
<td>0.470 ± 0.012</td>
<td>0.788 ± 0.025</td>
<td>0.966 ± 0.057</td>
<td>0.769 ± 0.013</td>
<td>0.417 ± 0.026</td>
</tr>
<tr>
<td>50 °C</td>
<td>225 ± 9</td>
<td>5.630 ± 0.205</td>
<td>1.063 ± 0.031</td>
<td>0.469 ± 0.014</td>
<td>0.763 ± 0.021</td>
<td>1.05 ± 0.022</td>
<td>0.795 ± 0.040</td>
<td>0.367 ± 0.011</td>
</tr>
<tr>
<td>Control-2</td>
<td>233 ± 3</td>
<td>5.830 ± 0.207</td>
<td>1.12 ± 0.029</td>
<td>0.467 ± 0.025</td>
<td>0.564 ± 0.065</td>
<td>0.915 ± 0.025</td>
<td>0.792 ± 0.008</td>
<td>0.347 ± 0.053</td>
</tr>
<tr>
<td>100 °C</td>
<td>233 ± 8</td>
<td>5.587 ± 0.854</td>
<td>1.160 ± 0.024</td>
<td>0.472 ± 0.014</td>
<td>0.644 ± 0.025</td>
<td>0.950 ± 0.022</td>
<td>0.793 ± 0.018</td>
<td>0.349 ± 0.025</td>
</tr>
</tbody>
</table>

Body weight (BW) and organ to body weight ratios, saturated vapor test, compound AI3-36161. Organ weights abbreviated as follows: Liver weight (LW), kidney weight (KW), heart weight (HW), lung weight (LWG), testes weight (TH), brain weight (BRW), spleen weight (SW). Numbers presented represent the mean ± standard error of the mean for six animals. There were no statistically significant differences among the three groups in any of the parameters.
**Table A.3: Summary of Physiological Data, Compound A35 36161**

<table>
<thead>
<tr>
<th></th>
<th>BP PRE</th>
<th>BP POST</th>
<th>HR PRE</th>
<th>HR POST</th>
<th>DRS PRE</th>
<th>DRS POST</th>
<th>GT PRE</th>
<th>GT POST</th>
<th>NW PRE</th>
<th>NW POST</th>
<th>PH PRE</th>
<th>PH POST</th>
<th>DM PRE</th>
<th>DM POST</th>
</tr>
</thead>
<tbody>
<tr>
<td>FPE</td>
<td>195 ± 12</td>
<td>158 ± 17</td>
<td>341 ± 47</td>
<td>226 ± 21</td>
<td>26 ± 2</td>
<td>32 ± 2</td>
<td>67 ± 7</td>
<td>62 ± 2</td>
<td>27 ± 2</td>
<td>15 ± 4</td>
<td>14 ± 2</td>
<td>15 ± 1</td>
<td>0.04 ± 0.02</td>
<td>0.05 ± 0.03</td>
</tr>
<tr>
<td>ACH</td>
<td>190 ± 6</td>
<td>71 ± 13</td>
<td>412 ± 11</td>
<td>319 ± 28</td>
<td>26 ± 2</td>
<td>36 ± 2</td>
<td>58 ± 1</td>
<td>59 ± 1</td>
<td>23 ± 2</td>
<td>21 ± 2</td>
<td>12 ± 1</td>
<td>14 ± 2</td>
<td>0.12 ± 0.01</td>
<td>0.12 ± 0.01</td>
</tr>
<tr>
<td>NE</td>
<td>163 ± 3</td>
<td>117 ± 14</td>
<td>420 ± 15</td>
<td>345 ± 19</td>
<td>29 ± 2</td>
<td>27 ± 1</td>
<td>62 ± 7</td>
<td>58 ± 1</td>
<td>24 ± 2</td>
<td>19 ± 3</td>
<td>13 ± 2</td>
<td>13 ± 2</td>
<td>0.13 ± 0.02</td>
<td>0.09 ± 0.01</td>
</tr>
<tr>
<td>WST</td>
<td>112 ± 10</td>
<td>67 ± 15</td>
<td>412 ± 10</td>
<td>412 ± 10</td>
<td>27 ± 2</td>
<td>27 ± 2</td>
<td>58 ± 1</td>
<td>59 ± 1</td>
<td>24 ± 2</td>
<td>19 ± 1</td>
<td>12 ± 2</td>
<td>12 ± 2</td>
<td>0.14 ± 0.01</td>
<td>0.07 ± 0.02</td>
</tr>
<tr>
<td>SAL</td>
<td>127 ± 9</td>
<td>87 ± 14</td>
<td>367 ± 11</td>
<td>307 ± 27</td>
<td>27 ± 2</td>
<td>27 ± 2</td>
<td>58 ± 1</td>
<td>58 ± 1</td>
<td>24 ± 2</td>
<td>17 ± 2</td>
<td>13 ± 2</td>
<td>13 ± 2</td>
<td>0.14 ± 0.01</td>
<td>0.09 ± 0.02</td>
</tr>
</tbody>
</table>

Values presented are the mean ± the standard error of the mean for five animals. Maximum changes in response to drug challenges were recorded. Data were analyzed with a two-way analysis of variance for repeated values. Table abbreviations are as follows: BP = blood pressure (mm Hg), HR = heart rate (beats/min), DRS = width of dose complex (mm), NW = width (mm), PH = height (millitls), DM = depth (millitls), PRE = pre-treatment response, POST = response to drug challenge 15 min post injection, FPE = equineprine, ACH = acetylcholine, NE = noradrenaline, WST = histamine, SAL = saline. *Indicates significant difference when compared to pre-exposure values (P < 0.05).
APPENDIX B
DEFINITIONS OF CATEGORIES OF SKIN AND EYE IRRITANTS

1. Skin irritants.
   a. **Category I** - Compounds producing no irritation of intact skin or no greater than mild primary irritation of the skin surrounding an abrasion.
   b. **Category II** - Compounds producing mild primary irritation of the intact skin and the skin surrounding an abrasion.
   c. **Category III** - Compounds producing moderate primary irritation of the intact skin and the skin surrounding an abrasion.
   d. **Category IV** - Compounds producing moderate to severe primary irritation of the intact skin and of the skin surrounding an abrasion and in addition, producing necrosis, vesiculation, and/or eschars.
   e. **Category V** - Compounds impossible to classify because of staining of the skin or other masking effects owing to physical properties of the compound.

2. Eye irritants.
   a. **Category A** - Compounds noninjurious to the eye.
   b. **Category B** - Compounds producing mild injury to the cornea.
   c. **Category C** - Compounds producing mild injury to the cornea and in addition some injury to the conjunctiva.
   d. **Category D** - Compounds producing moderate injury to the cornea.
   e. **Category E** - Compounds producing moderate injury to the cornea and in addition, some injury to the conjunctiva.
   f. **Category F** - Compounds producing severe injury to the cornea and to the conjunctiva.
APPENDIX C

PROJECT PERSONNEL

The experiments described in this report were performed by a multidisciplinary group under the direction of Glenn Leach. The group included the following:

1. Lynn M. Balczewski, SGT, Lab Animal Care Specialist.
2. John G. Harvey, Bio Lab Tech.
4. R. David Russell, CPT, VC.
END
12-86
DTC